Ying Chen1,2, Tao-Ran Li1, Shu-Wen Hao3, Xiao-Ni Wang1, Yan-Ning Cai3, Ying Han1,4,5. 1. Department of Neurology, Xuanwu Hospital of Capital Medical University, Beijing, China. 2. Department of Neurology, Zhejiang Taizhou Municipal Hospital, Taizhou, Zhejiang, China. 3. Department of Neurobiology, Xuanwu Hospital of Capital Medical University, Beijing, China. 4. Center of Alzheimer's Disease, Beijing Institute for Brain Disorders, Beijing, China. 5. National Clinical Research Center for Geriatric Disorders, Beijing, China.
Abstract
Objective: This study assessed the methylation of peripheral NCAPH2 in individuals with subjective cognitive decline (SCD), identified its correlation with the hippocampal volume, and explored whether the correlation is influenced by apolipoprotein E ε4 (APOE ε4) status. Methods: Cognitively normal controls (NCs, n = 56), individuals with SCD (n = 81), and patients with objective cognitive impairment (OCI, n = 51) were included from the Sino Longitudinal Study on Cognitive Decline (NCT03370744). All participants completed neuropsychological assessments, blood tests, and structural MRI. NCAPH2 methylation was compared according to the diagnostic and APOE ε4 status. Partial correlation analysis was conducted to assess the correlations between the hippocampal volume, cognitive tests, and the NCAPH2 methylation levels. Results: Individuals with SCD and patients with OCI showed significantly lower levels of NCAPH2 methylation than NCs, which were independent of the APOE ε4 status. The NCAPH2 methylation levels and the hippocampal volumes were positively correlated in the SCD APOE ε4 non-carriers but not in the OCI group. No association was found between the NCAPH2 methylation levels and the cognitive function. Conclusion: Abnormal changes in blood NCAPH2 methylation were found to occur in SCD, indicating its potential to be used as a useful peripheral biomarker in the early stage of Alzheimer's disease screening.
Objective: This study assessed the methylation of peripheral NCAPH2 in individuals with subjective cognitive decline (SCD), identified its correlation with the hippocampal volume, and explored whether the correlation is influenced by apolipoprotein E ε4 (APOE ε4) status. Methods: Cognitively normal controls (NCs, n = 56), individuals with SCD (n = 81), and patients with objective cognitive impairment (OCI, n = 51) were included from the Sino Longitudinal Study on Cognitive Decline (NCT03370744). All participants completed neuropsychological assessments, blood tests, and structural MRI. NCAPH2 methylation was compared according to the diagnostic and APOE ε4 status. Partial correlation analysis was conducted to assess the correlations between the hippocampal volume, cognitive tests, and the NCAPH2 methylation levels. Results: Individuals with SCD and patients with OCI showed significantly lower levels of NCAPH2 methylation than NCs, which were independent of the APOE ε4 status. The NCAPH2 methylation levels and the hippocampal volumes were positively correlated in the SCDAPOE ε4 non-carriers but not in the OCI group. No association was found between the NCAPH2 methylation levels and the cognitive function. Conclusion: Abnormal changes in blood NCAPH2 methylation were found to occur in SCD, indicating its potential to be used as a useful peripheral biomarker in the early stage of Alzheimer's disease screening.
Authors: S C F Marques; R Lemos; E Ferreiro; M Martins; A de Mendonça; I Santana; T F Outeiro; C M F Pereira Journal: Neuroscience Date: 2012-06-21 Impact factor: 3.590
Authors: Rachel F Buckley; Paul Maruff; David Ames; Pierrick Bourgeat; Ralph N Martins; Colin L Masters; Stephanie Rainey-Smith; Nicola Lautenschlager; Christopher C Rowe; Greg Savage; Victor L Villemagne; Kathryn A Ellis Journal: Alzheimers Dement Date: 2016-02-04 Impact factor: 21.566
Authors: Vijay K Ramanan; Shannon L Risacher; Kwangsik Nho; Sungeun Kim; Li Shen; Brenna C McDonald; Karmen K Yoder; Gary D Hutchins; John D West; Eileen F Tallman; Sujuan Gao; Tatiana M Foroud; Martin R Farlow; Philip L De Jager; David A Bennett; Paul S Aisen; Ronald C Petersen; Clifford R Jack; Arthur W Toga; Robert C Green; William J Jagust; Michael W Weiner; Andrew J Saykin Journal: Brain Date: 2015-08-11 Impact factor: 13.501
Authors: Jacob W Vogel; Monika Varga Doležalová; Renaud La Joie; Shawn M Marks; Henry D Schwimmer; Susan M Landau; William J Jagust Journal: Neurology Date: 2017-10-06 Impact factor: 9.910
Authors: V K Ramanan; S L Risacher; K Nho; S Kim; S Swaminathan; L Shen; T M Foroud; H Hakonarson; M J Huentelman; P S Aisen; R C Petersen; R C Green; C R Jack; R A Koeppe; W J Jagust; M W Weiner; A J Saykin Journal: Mol Psychiatry Date: 2013-02-19 Impact factor: 15.992
Authors: Shannon L Risacher; Eileen F Tallman; John D West; Karmen K Yoder; Gary D Hutchins; James W Fletcher; Sujuan Gao; David A Kareken; Martin R Farlow; Liana G Apostolova; Andrew J Saykin Journal: Alzheimers Dement (Amst) Date: 2017-09-23